Unraveling the mechanisms of IVIG immunotherapy in MIS-C

Madhusudan Ganigara; Chetan Sharma; Jagadeesh Bayry

doi:10.1016/j.xcrm.2021.100431

Unraveling the mechanisms of IVIG immunotherapy in MIS-C

Cell Rep Med. 2021 Oct 19;2(10):100431. doi: 10.1016/j.xcrm.2021.100431. Epub 2021 Sep 30.

Authors

Madhusudan Ganigara¹, Chetan Sharma², Jagadeesh Bayry³

Affiliations

¹ Division of Pediatric Cardiology, The University of Texas Southwestern Medical Center, Dallas, TX 75235, USA.
² Division of Pediatric Cardiology, Children's Hospital of San Antonio/Baylor College of Medicine, San Antonio, TX 78207, USA.
³ Biological Sciences & Engineering, Indian Institute of Technology Palakkad, Palakkad 678 623, Kerala, India.

Abstract

In The Journal of Clinical Investigation, Zhu et al.¹ report that intravenous immunoglobulin (IVIG) targets IL-1β⁺ neutrophils to exert anti-inflammatory effects in multisystem inflammatory syndrome in children (MIS-C), a post-infectious inflammatory condition associated with COVID-19.

Publication types

Research Support, Non-U.S. Gov't
Comment

MeSH terms

COVID-19* / complications
Child
Humans
Immunoglobulins, Intravenous* / therapeutic use
Immunotherapy
SARS-CoV-2
Systemic Inflammatory Response Syndrome

Substances

Immunoglobulins, Intravenous

Supplementary concepts

pediatric multisystem inflammatory disease, COVID-19 related